Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:51 07/05/2024 pm IST 5-day change 1st Jan Change
6,259 INR -0.66% Intraday chart for Dr. Reddy's Laboratories Limited -0.55% +7.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading MT
Dr. Reddy's Laboratories Fiscal Q4 Earnings, Revenue Gain MT
India's Dr Reddy's beats Q4 profit estimates RE
Dr. Reddy's Laboratories Limited Announces Cessation of Parag Agarwal as Member of Management Council CI
Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes CI
Dr. Reddy's Laboratories Limited Recommends Final Dividend for the Financial Year 2023-2024 CI
Dr. Reddy's Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Indian shares set to open higher on Fed rate-cut hopes RE
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher MT
Dr. Reddy's Laboratories Launches Generic Doxycycline Capsules in US MT
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S CI
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5% MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading MT
Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories DJ
Banking Stocks Lift Indian Equities Higher MT
Dr. Reddy's Laboratories Names CEO-North America MT
Dr. Reddy's Laboratories Limited Announces Executive Changes CI
Dr. Reddy's Laboratories Limited and Nestle India Limited Enter into Joint Venture Agreement for Investment in Dr. Reddy's Nutraceuticals Limited CI
Dr. Reddy's Laboratories Recalls Sapropterin Dihydrochloride Oral Solution Powder in US MT
Dr. Reddy's Laboratories Recalls Sapropterin Dihydrochloride Powder Over Potency Concerns MT
Dr. Reddy's Laboratories Limited Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 Mg Due to Sub-Potency CI
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
Dr. Reddy's Laboratories Limited Receives Complete Response Letter from FDA to Biologics License Application CI
Chart Dr. Reddy's Laboratories Limited
More charts
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,259 INR
Average target price
6,005 INR
Spread / Average Target
-4.06%
Consensus
  1. Stock Market
  2. Equities
  3. DRREDDY Stock
  4. News Dr. Reddy's Laboratories Limited
  5. Dr Reddy Laboratories : Launches Brain Tumor Treatment Drug in US
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW